InvestorsHub Logo
Followers 50
Posts 6343
Boards Moderated 0
Alias Born 01/22/2006

Re: None

Friday, 07/18/2008 7:18:05 AM

Friday, July 18, 2008 7:18:05 AM

Post# of 746
On the Gilead call they talked about starting a Phase 3 in IPF with Letairis. It would be 600 patients, 190 sites worldwide. They will look at disease progression/death. Seems they are going to follow Actelion/Tracleer in indication and design. My guess if Tracleer fails this won't get very far. I think some of the PAH drugs tried in IPF may face some added scrutiny or a narrow label since their is a significant number of IPF patients who have PAH.

EDIT: Despite what Gilead may say Letairis has been a disappointment and I suspect this is one avenue to try to salvage the drug. I have yet to see any studies or speculation on ERA and Pirfenidone working together. Dan Welch was once asked about it and said only that since the mechanisms are different it may be possible. To me as big an issue may be reimbursement for taking both at the same time.